Long‐term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy‐induced eyelash hypotrichosis: a randomized controlled trial

比马前列素 睫毛 医学 少毛症 随机对照试验 皮肤病科 不利影响 外科 眼科 内科学 青光眼 拉坦前列素 生物化学 化学 遗传学 生物 基因
作者
Dee Anna Glaser,Parwez Hossain,William Perkins,T.W. Griffiths,Gurpreet S. Ahluwalia,Emily Weng,Frederick C. Beddingfield
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:172 (5): 1384-1394 被引量:46
标识
DOI:10.1111/bjd.13443
摘要

Bimatoprost ophthalmic solution 0·03% is approved in several countries for the treatment of eyelash hypotrichosis. Previous trials were limited to 4 months of treatment and primarily idiopathic hypotrichosis.To evaluate the long-term safety and efficacy of bimatoprost in patients with idiopathic or chemotherapy-induced hypotrichosis.This multicentre, double-masked, randomized, parallel-group study included two 6-month treatment periods [treatment period 1 (TP1) and treatment period 2 (TP2)]. Patients with idiopathic hypotrichosis were randomized to three treatment groups: (i) bimatoprost (TP1 and TP2); (ii) bimatoprost (TP1) and vehicle (TP2); and (iii) vehicle (TP1) and bimatoprost (TP2). Patients with chemotherapy-induced hypotrichosis were randomized to two treatment groups: (i) bimatoprost or vehicle (TP1) and (ii) bimatoprost (TP2). Primary end point was a composite of at least a one-grade improvement in investigator-assessed Global Eyelash Assessment and at least a three-point improvement in patient-reported Eyelash Satisfaction Questionnaire Domain 2 at month 4. Secondary measures included digitally assessed eyelash characteristics.The primary efficacy end point was met in both populations (idiopathic responder rate was 40·2% for bimatoprost vs. 6·8% for vehicle; postchemotherapy responder rate was 37·5% for bimatoprost vs. 18·2% for vehicle). Efficacy by month 6 was maintained (idiopathic) or enhanced (postchemotherapy) at 12 months. Treatment effects were maintained for approximately 2 months but markedly diminished 4-6 months following treatment cessation in patients with idiopathic hypotrichosis. No drug-related serious adverse events were reported.Daily treatment with bimatoprost ophthalmic solution 0·03% for 1 year was effective and well tolerated in patients with idiopathic and chemotherapy-induced hypotrichosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
www完成签到 ,获得积分10
3秒前
科研通AI6.2应助banxia002采纳,获得30
3秒前
情怀应助soki采纳,获得10
3秒前
一个one子完成签到 ,获得积分10
4秒前
cency发布了新的文献求助10
5秒前
Aimee完成签到 ,获得积分10
6秒前
6秒前
7秒前
科研通AI2S应助Robin95采纳,获得10
7秒前
菘蓝完成签到,获得积分10
8秒前
9秒前
Jasper应助Bigwang采纳,获得10
9秒前
133完成签到 ,获得积分10
13秒前
13秒前
竹醉先生完成签到,获得积分10
14秒前
Chow发布了新的文献求助10
14秒前
cdercder应助拾光采纳,获得10
15秒前
聪慧芸完成签到 ,获得积分10
15秒前
花开富贵完成签到,获得积分10
17秒前
19秒前
linyudie完成签到,获得积分10
19秒前
海纳百川完成签到,获得积分10
21秒前
追寻觅夏发布了新的文献求助10
21秒前
青青儿完成签到 ,获得积分10
22秒前
23秒前
高g完成签到,获得积分10
23秒前
SciGPT应助小凯采纳,获得10
24秒前
蟑螂恶霸发布了新的文献求助10
24秒前
彭于晏应助linyudie采纳,获得10
24秒前
好的哥完成签到,获得积分10
25秒前
soki发布了新的文献求助10
25秒前
鹏虫虫完成签到 ,获得积分10
28秒前
追寻觅夏完成签到,获得积分10
29秒前
花开富贵发布了新的文献求助10
29秒前
英俊的铭应助luo采纳,获得10
29秒前
Doria完成签到 ,获得积分10
30秒前
暮雨杰泽完成签到 ,获得积分10
31秒前
31秒前
搜集达人应助Velarok采纳,获得10
31秒前
31秒前
高分求助中
The Graphene Handbook (2019 Edition) 800
Signals, Systems, and Signal Processing 610
IEST-RP-CC018: Cleanroom Cleaning and Sanitization: Operating and Monitoring Procedures 600
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
久松真一著作集〈第5巻〉禅と芸術 500
Fundamentals of Modern Mathematics: A Practical Review (Dover Books on Mathematics) 500
Cold War Transcended: Australia's China Policy, 1949-1990 470
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6598686
求助须知:如何正确求助?哪些是违规求助? 8368168
关于积分的说明 17911509
捐赠科研通 5752740
什么是DOI,文献DOI怎么找? 2953813
邀请新用户注册赠送积分活动 1929056
关于科研通互助平台的介绍 1823875